KRSA

36.9854.33%
HH

Heidi Henson

Independent Director

Ms. Heidi Henson, CPA, is Independent Director of Korsana Biosciences, Inc. from June 2026. Ms. Henson has more than two decades of financial operations experience across public and private biopharmaceutical companies. Ms. Henson serves as Independent Director for Perspective Therapeutics, Inc. since 2023. She has been an Independent Director of PepGen Inc. since July 2021. She is an Independent Director at Lisata Therapeutics, Inc. from September 2022. Ms. Henson was Director of Perspective Therapeutics, Inc. since June 1, 2023 until 2023. She served as Chief Financial Officer of Pardes Biosciences, Inc. since January 2021. She was previously an advisor to Pardes Biosciences, Inc. from April 2020 to January 2021. Ms. Henson also serves as a Member of the Board of Directors of Cend Therapeutics. She has financial operations experience with both public and private companies. She previously held financial and operational leadership roles at other biotechnology companies including Imbria Pharmaceuticals, Kura Oncology (Nasdaq:KURA), Wellspring Biosciences, Inc. (as well as its parent company Araxes Pharma LLC) and Intellikine Inc. which was acquired by Takeda Pharmaceutical Company Limited. She served as Chief Financial Officer of Araxes Pharma LLC, from July 2012 to July 2018. She served as Chief Financial Officer of Respivant Sciences from November 2018 to April 2019. Ms. Henson was Chief Financial Officer of Imbria Pharmaceuticals, Inc. from April 2019 to July 2020. She was Chief Financial Officer and Secretary at Kura Oncology, Inc. from August 2014 to July 06, 2018. Ms. Henson served as Chief Financial Officer of Wellspring Biosciences LLC since July 2012 and served as its Secretary from July 2012 to January 2015. Ms. Henson also served as Chief Financial Officer of Wellspring Biosciences, Inc. She served as a Director of Finance at Intellikine, Inc. She served as the Chief Financial Officer and Secretary of Prior Kura from August 2014 until the Upstream Merger in March 2015. She served as Secretary of Araxes Pharma, LLC since July 2012 until January 2015 Ms. Henson joined Intellikine, Inc. in 2007. From 2007 to March 2012, Ms. Henson served as the Vice President of Finance at Intellikine, Inc. until its acquisition by Takeda Pharmaceutical Company Limited. She served as a Director of Finance at Anadys Pharmaceuticals Inc. from January 2003 to September 2004 and served as Principal Accounting Officer until September 2004. Ms. Henson has served as an independent financial consultant for many years assisting companies with various start-up activities for early-stage companies, SEC reporting and Sarbanes-Oxley implementation and compliance. She held a number of management positions with Fair Isaac & Co. Inc. a developer of predictive software solutions. She served as Anadys Pharmaceuticals Inc.'s Controller from November 2002 to January 2003. From 1996 to 2002, Ms. Henson worked at Fair Isaac Corporation, a publicly traded company which was formerly HNC Software Inc. where she held a variety of positions includes Director, Internal Audit; Controller for the eHNC division; Assistant Corporate Controller; Financial Reporting Manager and Senior Financial Analyst. From March 1996 to August 1996, she served as Financial Analyst for Alaris Medical Systems, Inc. which was formerly IVAC Medical Systems, Inc. and from 1992 to 1996 she was an Auditor with PricewaterhouseCoopers LLP, where she began her career in auditing and served both public and private companies. She is Director of Cend Therapeutics Inc. Ms. Henson received her Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive) in the state of California.

Positions